Novatreat

Novatreat is a Finnish biotechnology company specializing in the development of live biotherapeutic products (LBPs) for the treatment of inflammatory skin diseases. The company's lead candidate, NT-001, is a topical probiotic formulation designed to restore the balance of the skin microbiome in patients with atopic dermatitis. By leveraging specific bacterial strains, Novatreat aims to provide a safe and effective alternative to traditional steroid-based treatments. The company's research is rooted in the understanding of the skin-gut axis and the role of beneficial microbes in immune regulation. Novatreat is currently advancing its clinical programs to address the high unmet need in chronic dermatological conditions.